Heat shock protein 90 inhibition: Rationale and clinical potential

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 4, 2012, Pages 211-218

  Den, Robert B ^a   Lu, Bo ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

clinical trial; heat shock protein 90; pharmacological inhibition

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALVESPIMYCIN; AT 13387; BORTEZOMIB; DOCETAXEL; EVEROLIMUS; GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; KW 2478; PROTEASOME; RETASPIMYCIN; RITUXIMAB; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANOXIA; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL STRESS; CLINICAL TRIAL; HUMAN; PH; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

EID: 84866549191     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012445574     Document Type: Review

References (54)

1. Banerji U. O'Donnell A. Scurr M. Pacey S. Stapleton S. Asad Y. et al. (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152–4161.
2. Bao R. Lai C.J. Qu H. Wang D. Yin L. Zifcak B. et al. (2009) CUDC-305, a novel synthetic HSP 90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 15: 4046–4057.
3. Barluenga S. Wang C. Fontaine J.G. Aouadi K. Beebe K. Tsutsumi S. et al. (2008) Divergent synthesis of a pochonin library targeting HSP 90 and in vivo efficacy of an identified inhibitor. Angew Chem Int Ed Engl 47: 4432–4435.
4. Blagosklonny M.V. (2001) Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 93: 239–240.
5. Bonvini P. Gastaldi T. Falini B. Rosolen A. (2002) Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp 90 antagonist 17-allylamino,17-demethoxygeldanamycin. Cancer Res 62: 1559–1566.
6. Brough P.A. Barril X. Borgognoni J. Chene P. Davies N.G. Davis B. et al. (2009) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp 90 molecular chaperone. J Med Chem 52: 4794–4809.
7. Chandarlapaty S. Sawai A. Ye Q. Scott A. Silinski M. Huang K. et al. (2008) SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14: 240–248.
8. Chant I.D. Rose P.E. Morris A.G. (1995) Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 90: 163–168.
9. Ciocca D.R. Clark G.M. Tandon A.K. Fuqua S.A. Welch W.J. McGuire W.L. (1993) Heat shock protein hsp 70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 85: 570–574.
10. Cysyk R.L. Parker R.J. Barchi J.J. Jr Steeg P.S. Hartman N.R. Strong J.M. (2006) Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 19: 376–381.
11. Douglas M. Lim A.R. Porter J.R. West K. Pink M.M. Ge J. et al. (2009) The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo. Mol Cancer Ther 8: 3369–3378.
12. Egorin M.J. Rosen D.M. Wolff J.H. Callery P.S. Musser S.M. Eiseman J.L. (1998) Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58: 2385–2396.
13. Floris G. Sciot R. Wozniak A. van Looy T. Wellens J. Faa G. et al. (2011) The novel HSP 90 inhibitor, IPI-493, is highly effective in human gastrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res 17: 5604–5614.
14. Ge J. Normant E. Porter J.R. Ali J.A. Dembski M.S. Gao Y. et al. (2006) Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 49: 4606–4615.
15. Glaze E.R. Lambert A.L. Smith A.C. Page J.G. Johnson W.D. McCormick D.L. et al. (2005) Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56: 637–647.
16. Goetz M.P. Toft D.O. Ames M.M. Erlichman C. (2003) The Hsp 90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14: 1169–1176.
17. Grem J.L. Morrison G. Guo X.D. Agnew E. Takimoto C.H. Thomas R. et al. (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23: 1885–1893.
18. Guo W. Reigan P. Siegel D. Zirrolli J. Gustafson D. Ross D. (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65: 10006–10015.
19. Holland J.P. Caldas-Lopes E. Divilov V. Longo V.A. Taldone T. Zatorska D. et al. (2010) Measuring the pharmacodynamic effects of a novel Hsp 90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PloS ONE 5: e8859.
20. Isaacs J.S. Xu W. Neckers L. (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213–217.
21. Jameel A. Skilton R.A. Campbell T.A. Chander S.K. Coombes R.C. Luqmani Y.A. (1992) Clinical and biological significance of HSP 89 alpha in human breast cancer. Int J Cancer 50: 409–415.
22. Kamal A. Thao L. Sensintaffar J. Zhang L. Boehm M.F. Fritz L.C. et al. (2003) A high-affinity conformation of Hsp 90 confers tumour selectivity on Hsp 90 inhibitors. Nature 425: 407–410.
23. Kaur J. Ralhan R. (1995) Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int J Cancer 63: 774–779.
24. Kim Y.S. Alarcon S.V. Lee S. Lee M.J. Giaccone G. Neckers L. et al. (2009) Update on Hsp 90 inhibitors in clinical trial. Curr Top Med Chem 9: 1479–1492.
25. Knapper S. (2007) FLT 3 inhibition in acute myeloid leukaemia. Br J Haematol 138: 687–699.
26. Kummar S. Gutierrez M.E. Gardner E.R. Chen X. Figg W.D. Zajac-Kaye M. et al. (2010) Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46: 340–347.
27. Lancet J.E. Gojo I. Burton M. Quinn M. Tighe S.M. Kersey K. et al. (2010) Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24: 699–705.
28. Lin T.Y. Bear M. Du Z. Foley K.P. Ying W. Barsoum J. et al. (2008) The novel HSP 90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors. Exp Hematol 36: 1266–1277.
29. Mahalingam D. Swords R. Carew J.S. Nawrocki S.T. Bhalla K. Giles F.J. (2009) Targeting HSP 90 for cancer therapy. Br J Cancer 100: 1523–1529.
30. Menzella H.G. Tran T.T. Carney J.R. Lau-Wee J. Galazzo J. Reeves C.D. et al. (2009) Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus. J Med Chem 52: 1518–1521.
31. Modi S. Stopeck A.T. Gordon M.S. Mendelson D. Solit D.B. Bagatell R. et al. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer:a phase I dose-escalation study. J Clin Oncol 25: 5410–5417.
32. Morimoto R.I. Kline M.P. Bimston D.N. Cotto J.J. (1997) The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem 32: 17–29.
33. Nagengast W.B. de Korte M.A. Oude Munnink T.H. Timmer-Bosscha H. den Dunnen W.F. Hollema H. et al. (2010) 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP 90 inhibitor NVP-AUY922. J Nucl Med 51: 761–767.
34. Neckers L. (2007) Heat shock protein 90: the cancer chaperone. J Biosci 32: 517–530.
35. Peng C. Li D. Li S. (2007) Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 6: 2227–2231.
36. Rajan A. Kelly R.J. Trepel J.B. Kim Y.S. Alarcon S.V. Kummar S. et al. (2011) A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17: 6831–6839.
37. Ramanathan R.K. Egorin M.J. Erlichman C. Remick S.C. Ramalingam S.S. Naret C. et al. (2010) Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 28: 1520–1526.
38. Richardson P.G. Mitsiades C.S. Laubach J.P. Lonial S. Chanan-Khan A.A. Anderson K.C. (2011) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 152: 367–379.
39. Ritossa F. (1996) Discovery of the heat shock response. Cell Stress Chaperones 1: 97–98.
40. Roe S.M. Prodromou C. O'Brien R. Ladbury J.E. Piper P.W. Pearl L.H. (1999) Structural basis for inhibition of the Hsp 90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42: 260–266.
41. Sepp-Lorenzino L. Ma Z. Lebwohl D.E. Vinitsky A. Rosen N. (1995) Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem 270: 16580–16587.
42. Shimamura T. Lowell A.M. Engelman J.A. Shapiro G.I. (2005) Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 65: 6401–6408.
43. Smith-Jones P.M. Solit D. Afroze F. Rosen N. Larson S.M. (2006) Early tumor response to Hsp 90 therapy using HER 2 PET: comparison with 18F-FDG PET. J Nucl Med 47: 793–796.
44. Sydor J.R. Normant E. Pien C.S. Porter J.R. Ge J. Grenier L. et al. (2006) Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti- cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 103: 17408–17413.
45. Trepel J. Mollapour M. Giaccone G. Neckers L. (2010) Targeting the dynamic HSP 90 complex in cancer. Nat Rev Cancer 10: 537–549.
46. Uehara Y. (2003) Natural product origins of Hsp 90 inhibitors. Curr Cancer Drug Targets 3: 325–330.
47. Whitesell L. Lindquist S.L. (2005) HSP 90 and the chaperoning of cancer. Nat Rev Cancer 5: 761–772.
48. Whitesell L. Mimnaugh E.G. de Costa B. Myers C.E. Neckers L.M. (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91: 8324–8328.
49. Workman P. Burrows F. Neckers L. Rosen N. (2007) Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113: 202–216.
50. Xu W. Mimnaugh E. Rosser M.F. Nicchitta C. Marcu M. Yarden Y. et al. (2001) Sensitivity of mature Erbb 2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276: 3702–3708.
51. Yang Z.Q. Geng X. Solit D. Pratilas C.A. Rosen N. Danishefsky S.J. (2004) New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp 90 as the target. J Am Chem Soc 126: 7881–7889.
52. Yufu Y. Nishimura J. Nawata H. (1992) High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res 16: 597–605.
53. Zhang M.Q. Gaisser S. Nur E.A.M. Sheehan L.S. Vousden W.A. Gaitatzis N. et al. (2008) Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp 90 inhibitors. J Med Chem 51: 5494–5497.
54. Zhang T. Li Y. Yu Y. Zou P. Jiang Y. Sun D. (2009) Characterization of celastrol to inhibit hsp 90 and cdc 37 interaction. J Biol Chem 284: 35381–35389.